Please login to the form below
RIPK1 inhibitor
This page shows the latest RIPK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors
Rigel already has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates. ... The ethos behind RIPK1 inhibitor development is to offer a new kind of approach towards treating a range of autoimmune, inflammatory and
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- Create Health Showreel
- AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn
- Cancer Research UK urges government to realise ‘science superpower’ ambitions as new report highlights ‘huge’ economic value
- Novartis UK launches first health-tech investor partnership to address cardiovascular care
- UK government invests £175m to ‘supercharge’ clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- European Commission approves potential new treatment for Pompe disease
- Sanofi Global Health unveils new nonprofit Impact brand
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis UK launches first health-tech investor partnership to address cardiovascular care
PMHub
Medscape Education Global
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....
Latest intelligence
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
